News Briefs: CMS Will Continue Medicare Drug Price Negotiations, Gene Therapy Model
-
Jan 31, 2025
The Trump administration plans to continue with the Inflation Reduction Act’s Medicare Drug Price Negotiation Program as well as a model to help state Medicaid agencies pay for expensive cell and gene therapies. CMS said in a Jan. 29 statement that the agency “is committed to incorporating lessons learned to date” from the price negotiation program, and CMS will consider “opportunities to bring greater transparency” into the program. On Jan. 17, three days before Trump’s inauguration, CMS released the list of 15 drugs selected for the second cycle of the program. Meanwhile, an HHS spokesperson told STAT that the administration will continue with the Cell and Gene Therapy (CGT) Access Model, which CMS introduced in 2023 and is set to go into effect later this year. Trump’s recent recission of former President Joe Biden’s executive order that led to the creation of the model caused confusion about whether the CGT Access Model would continue during his administration. CMS last month announced the manufacturers of two high-cost sickle cell gene therapies will participate in the model.
Read more© 2024 MMIT

The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.